Immunogenicity of HPV Vaccine in Transplant Recipients.

Running, not enrolling · Phase 4

Conditions studied: Chronic Kidney Diseases, Kidney Transplant

In brief

To measure levels of HPV antibodies in post-solid-organ transplant recipients who have gotten the HPV9 vaccine.

Key facts

Study ID

NCT05557370

Run by

Medical College of Wisconsin

People needed

30

Starts

2023-06-01

Expected to finish

2035-12-31

Last updated by the study team

2026-05-01

Who can join

Age: 18 and older, up to 45. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient between the age of 18 and 45 years
• Patient is at least 6 months post-solid-organ transplant and has not received GARDASIL 9.
• Patient who can participate in their health care and sign informed consent.
• Patient may have had bivalent or quadrivalent HPV vaccination previously.
• Living or deceased donor transplant patient is eligible.

You may not qualify if…

• Contraindication: Hypersensitivity, including severe allergic reactions to yeast (a vaccine component), or after a previous dose of GARDASIL 9 or GARDASIL.
• Patient had completed vaccination series with a nonavalent HPV vaccine (e.g., GARDASIL 9) in the past
• Patient with a diagnosis of HIV.
• Patient that endorses being currently pregnant.

Where it is running

• Froedtert Lutheran Memorial Hospital — Milwaukee, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.